Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• Hepatocellular carcinoma (HCC) relies on aberrant gene transcription for growth.
• Super-enhancers (SEs) are crucial for maintaining high oncogene expression in cancer cells.

Purpose of the Study:

• To compare SE landscapes in normal liver and HCC cells.
• To investigate the role of SEs and their components in HCC progression.
• To evaluate therapeutic strategies targeting the SE complex in HCC.

Main Methods:

• Systematic comparison of SE landscapes using genomic analysis.
• Identification of SE-associated oncogenes (e.g., SPHK1).
• CRISPR/Cas9 gene editing and small-molecule inhibitors (e.g., THZ1) to target SE complex components (CDK7, BRD4, EP300, MED1).
• In vitro and in vivo HCC models for therapeutic evaluation.

Main Results:

• Extensive reprogramming of the SE landscape during liver carcinogenesis.
• Acquisition of SEs at prominent oncogenes in HCC cells.
• Frequent overexpression of SE complex components (CDK7, BRD4, EP300, MED1) linked to poor HCC prognosis.
• HCC cells are sensitive to SE complex perturbations, leading to selective oncogene repression.
• THZ1 (a CDK7 inhibitor) demonstrated significant anticancer effects in HCC models.

Conclusions:

• The SE landscape and machinery are significantly altered in HCC.
• HCC cells are highly susceptible to targeting the SE complex, selectively suppressing oncogenes.
• Targeting the SE complex represents a promising therapeutic strategy for HCC.